Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, tolerability, and pharmacokinetics study of MK-8507 and once-weekly islatravir + MK-8507 in healthy Japanese adults
jRCT2031250655Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Trial of ulonivirine and islatravir in human immunodeficiency virus infection (HIV) (5 arms), sponsored by Merck & Co. Primary endpoints: Adverse events, Discontinuation due to adverse events and 1 more. Started Apr 2026; status: active, not recruiting.
02
Drugs
ulonivirineislatravir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on jRCT2031250655.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250655.